Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 1
2012 4
2013 3
2014 1
2015 2
2020 1
2021 0
Text availability
Article attribute
Article type
Publication date

Search Results

10 results
Results by year
Filters applied: . Clear all
Page 1
Real-Time PCR Assays for the Specific Identification of Probiotic Strains Lactobacillus gasseri BNR17 and Lactobacillus reuteri LRC (NCIMB 30242).
Shehata HR, Ragupathy S, Allen S, Leyer G, Newmaster SG. Shehata HR, et al. Probiotics Antimicrob Proteins. 2020 Aug 11. doi: 10.1007/s12602-020-09695-y. Online ahead of print. Probiotics Antimicrob Proteins. 2020. PMID: 32780278
Both Lactobacillus gasseri BNR17 and Lactobacillus reuteri LRC (NCIMB 30242) strains have clinically proven health benefits; however, no assays were developed to enable strain-level identification of either of these strains. ...
Both Lactobacillus gasseri BNR17 and Lactobacillus reuteri LRC (NCIMB 30242) strains have clinically proven health benefits; h …
Cholesterol lowering and inhibition of sterol absorption by Lactobacillus reuteri NCIMB 30242: a randomized controlled trial.
Jones ML, Martoni CJ, Prakash S. Jones ML, et al. Eur J Clin Nutr. 2012 Nov;66(11):1234-41. doi: 10.1038/ejcn.2012.126. Epub 2012 Sep 19. Eur J Clin Nutr. 2012. PMID: 22990854 Clinical Trial.
Subjects were randomized to consume L. reuteri NCIMB 30242 capsules or placebo capsules over a 9-week intervention period. ...CONCLUSIONS: The present results suggest that the deconjugation of intraluminal bile acids results in reduced absorption of non-cholesterol …
Subjects were randomized to consume L. reuteri NCIMB 30242 capsules or placebo capsules over a 9-week intervention period. ... …
Cholesterol-lowering efficacy of a microencapsulated bile salt hydrolase-active Lactobacillus reuteri NCIMB 30242 yoghurt formulation in hypercholesterolaemic adults.
Jones ML, Martoni CJ, Parent M, Prakash S. Jones ML, et al. Br J Nutr. 2012 May;107(10):1505-13. doi: 10.1017/S0007114511004703. Epub 2011 Nov 9. Br J Nutr. 2012. PMID: 22067612 Clinical Trial.
Present results show that consumption of microencapsulated BSH-active L. reuteri NCIMB 30242 yoghurt is efficacious and safe for lowering LDL-C, TC, apoB-100 and non-HDL-C in hypercholesterolaemic subjects. The efficacy of microencapsulated BSH-active L. reuteri …
Present results show that consumption of microencapsulated BSH-active L. reuteri NCIMB 30242 yoghurt is efficacious and safe f …
Effect of probiotics on biomarkers of cardiovascular disease: implications for heart-healthy diets.
DiRienzo DB. DiRienzo DB. Nutr Rev. 2014 Jan;72(1):18-29. doi: 10.1111/nure.12084. Epub 2013 Dec 13. Nutr Rev. 2014. PMID: 24330093 Review.
Significant LDL-C reductions were observed for four probiotic strains: Lactobacillus reuteri NCIMB 30242, Enterococcus faecium, and the combination of Lactobacillus acidophilus La5 and Bifidobacterium lactis Bb12. ...Based on these results, the probiotic L. reuteri …
Significant LDL-C reductions were observed for four probiotic strains: Lactobacillus reuteri NCIMB 30242, Enterococcus faecium …
Evaluation of clinical safety and tolerance of a Lactobacillus reuteri NCIMB 30242 supplement capsule: a randomized control trial.
Jones ML, Martoni CJ, Di Pietro E, Simon RR, Prakash S. Jones ML, et al. Regul Toxicol Pharmacol. 2012 Jul;63(2):313-20. doi: 10.1016/j.yrtph.2012.04.003. Epub 2012 Apr 25. Regul Toxicol Pharmacol. 2012. PMID: 22561556 Clinical Trial.
In the present study, the clinical safety and toxicology of oral ingestion of supplement capsules containing L. reuteri NCIMB 30242 was investigated. A randomized group of 131 subjects received a dose of 2.9109 CFU L. reuteri NCIMB 30242 capsules (n=67 …
In the present study, the clinical safety and toxicology of oral ingestion of supplement capsules containing L. reuteri NCIMB 3024
Oral supplementation with probiotic L. reuteri NCIMB 30242 increases mean circulating 25-hydroxyvitamin D: a post hoc analysis of a randomized controlled trial.
Jones ML, Martoni CJ, Prakash S. Jones ML, et al. J Clin Endocrinol Metab. 2013 Jul;98(7):2944-51. doi: 10.1210/jc.2012-4262. Epub 2013 Apr 22. J Clin Endocrinol Metab. 2013. PMID: 23609838 Clinical Trial.
Subjects were recruited from 6 private practices in Prague, Czech Republic, and randomized to consume L. reuteri NCIMB 30242 or placebo capsules over a 9-week intervention period. ...RESULTS: There were no significant differences between L. reuteri NCIMB 3
Subjects were recruited from 6 private practices in Prague, Czech Republic, and randomized to consume L. reuteri NCIMB 30242 o …
Changes in bile acids, FGF-19 and sterol absorption in response to bile salt hydrolase active L. reuteri NCIMB 30242.
Martoni CJ, Labbé A, Ganopolsky JG, Prakash S, Jones ML. Martoni CJ, et al. Gut Microbes. 2015;6(1):57-65. doi: 10.1080/19490976.2015.1005474. Gut Microbes. 2015. PMID: 25612224 Free PMC article. Clinical Trial.
Disrupted regulation of BA metabolism is implicated in several chronic diseases. Bile salt hydrolase (BSH)-active Lactobacillus reuteri NCIMB 30242, previously shown to decrease LDL-cholesterol and increase circulating BA, was investigated for its dose response effe …
Disrupted regulation of BA metabolism is implicated in several chronic diseases. Bile salt hydrolase (BSH)-active Lactobacillus reuteri N
Evaluation of safety and tolerance of microencapsulated Lactobacillus reuteri NCIMB 30242 in a yogurt formulation: a randomized, placebo-controlled, double-blind study.
Jones ML, Martoni CJ, Tamber S, Parent M, Prakash S. Jones ML, et al. Food Chem Toxicol. 2012 Jun;50(6):2216-23. doi: 10.1016/j.fct.2012.03.010. Epub 2012 Mar 15. Food Chem Toxicol. 2012. PMID: 22425689 Clinical Trial.
Previously, we have reported on the efficacy of microencapsulated Lactobacillus reuteri NCIMB 30242 in a yogurt formulation at lowering serum cholesterol levels in otherwise healthy hypercholesterolemic adults. This study investigates the safety and toxicology of or …
Previously, we have reported on the efficacy of microencapsulated Lactobacillus reuteri NCIMB 30242 in a yogurt formulation at …
Improvement of gastrointestinal health status in subjects consuming Lactobacillus reuteri NCIMB 30242 capsules: a post-hoc analysis of a randomized controlled trial.
Jones ML, Martoni CJ, Ganopolsky JG, Sulemankhil I, Ghali P, Prakash S. Jones ML, et al. Expert Opin Biol Ther. 2013 Dec;13(12):1643-51. doi: 10.1517/14712598.2013.833601. Epub 2013 Sep 28. Expert Opin Biol Ther. 2013. PMID: 24074303 Clinical Trial.
A post-hoc analysis has been undertaken to evaluate the effect of bile salt hydrolase-active L. reuteri NCIMB 30242 on GI health status based on Rome III questionnaire response in otherwise healthy hypercholesterolemic subjects. RESEARCH DESIGN/METHODS: A total of 1 …
A post-hoc analysis has been undertaken to evaluate the effect of bile salt hydrolase-active L. reuteri NCIMB 30242 on GI heal …
Impact of a yogurt matrix and cell microencapsulation on the survival of Lactobacillus reuteri in three in vitro gastric digestion procedures.
Champagne CP, Raymond Y, Guertin N, Martoni CJ, Jones ML, Mainville I, Arcand Y. Champagne CP, et al. Benef Microbes. 2015;6(5):753-63. doi: 10.3920/BM2014.0162. Epub 2015 Jun 3. Benef Microbes. 2015. PMID: 26036146
The goal of this study was to assess the interaction between microencapsulation and a yogurt food matrix on the survival of Lactobacillus reuteri NCIMB 30242 in four different in vitro systems that simulate a gastric environment. ...
The goal of this study was to assess the interaction between microencapsulation and a yogurt food matrix on the survival of Lactobacillus re …